Pure Global

A Study for HSK39775 in Participants With Solid Tumors - Trial NCT06314373

Access comprehensive clinical trial information for NCT06314373 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Xizang Haisco Pharmaceutical Co., Ltd and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 243 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06314373
Phase 1/2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06314373
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study for HSK39775 in Participants With Solid Tumors
A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies

Study Focus

Advanced Solid Tumors

HSK39775 Monotherapy

Interventional

drug

Sponsor & Location

Xizang Haisco Pharmaceutical Co., Ltd

Haisco Pharmaceutical Group Co., Ltd.

Shanghai, China

Timeline & Enrollment

Phase 1/2

Mar 07, 2024

Sep 01, 2028

243 participants

Primary Outcome

AE/SAE,DLT,MTD/MAD

Summary

This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer
 activity in patients with advanced solid tumors.

ICD-10 Classifications

Malignant neoplasm: Prepuce
Carcinoma in situ, unspecified
Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm: Parametrium
Malignant neoplasm: Orbit

Data Source

ClinicalTrials.gov

NCT06314373

Non-Device Trial